Cover Image
市場調查報告書

支氣管炎:開發中產品分析

Bronchitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232856
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
支氣管炎:開發中產品分析 Bronchitis - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 61 Pages
簡介

支氣管炎是指支氣管內側引起發炎的狀態。支氣管將空氣運出肺。症狀有產生痰和咳嗽來,痰中攙雜血。還有激烈地或中度運動引起嚴重的呼吸急促,此外還有讓症狀惡化的呼吸系統感染疾病頻發,喘鳴和疲勞,腳踝的疼痛,頭痛等。危險因素為抽煙,低抵抗力及胃逆流等。

本報告提供支氣管炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

支氣管炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;各企業
  • 企業開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Advanced Inhalation Therapies (AIT) Ltd
  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Han Wha Pharma Co Ltd
  • 杏林藥業
  • Merck & Co Inc
  • Mucosis BV
  • Orbis Biosciences Inc
  • Therabron Therapeutics Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9759IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchitis - Pipeline Review, H2 2017, provides an overview of the Bronchitis (Respiratory) pipeline landscape.

Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked, shortness of breath aggravated by exertion or mild activity, frequent respiratory infections that worsen symptom, wheezing, fatigue, ankle that affects both sides and headaches. Risk factors include smoking, low resistance and gastric reflux.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Bronchitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 2, 2 and 3 respectively.

Bronchitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchitis (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bronchitis - Overview
    • Bronchitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Bronchitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bronchitis - Companies Involved in Therapeutics Development
    • Advanced Inhalation Therapies (AIT) Ltd
    • AstraZeneca Plc
    • DBV Technologies SA
    • F. Hoffmann-La Roche Ltd
    • Han Wha Pharma Co Ltd
    • Kyorin Pharmaceutical Co Ltd
    • Merck & Co Inc
    • Mucosis BV
    • Orbis Biosciences Inc
    • Therabron Therapeutics Inc
  • Bronchitis - Drug Profiles
    • alteplase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-9668 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-367 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cyclosporine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HOB-051 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lascufloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitric oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prednisone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • respiratory syncytial virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YJP-40 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bronchitis - Dormant Projects
  • Bronchitis - Discontinued Products
  • Bronchitis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 23, 2017: Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome
      • Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
      • Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings
      • Feb 03, 2014: AIT To Present Noxcurebr At The Annual Meeting Of The Israeli Association Of Clinical Pediatrics
      • Jan 19, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants
      • Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine
      • Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA
      • Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bronchitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Bronchitis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2017
  • Bronchitis - Pipeline by AstraZeneca Plc, H2 2017
  • Bronchitis - Pipeline by DBV Technologies SA, H2 2017
  • Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Bronchitis - Pipeline by Han Wha Pharma Co Ltd, H2 2017
  • Bronchitis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Bronchitis - Pipeline by Merck & Co Inc, H2 2017
  • Bronchitis - Pipeline by Mucosis BV, H2 2017
  • Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2017
  • Bronchitis - Pipeline by Therabron Therapeutics Inc, H2 2017
  • Bronchitis - Dormant Projects, H2 2017
  • Bronchitis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Bronchitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Bronchitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top